YL-109 is an antitumor agent that can induce carboxyl terminus of Hsp70-interacting protein (CHIP) expression through aryl hydrocarbon receptor (AhR) signaling. YL-109 has ability to inhibit breast cancer cell growth and invasiveness.
性状
Solid
体外研究(In Vitro)
YL-109 (0.001-10 μM; 96 h or 24 h) inhibits cell proliferation, motility, and invasiveness in breast cancer cells.
YL-109 (1 μM) increases both CHIP mRNA and protein levels in MDA-MB-231 cells.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay
Cell Line:
MCF-7 and MDA-MB-231 cells
Concentration:
0.001, 0.01, 0.1, 1, 10 μM
Incubation Time:
96 hours
Result:
Strongly inhibited cell proliferation of MCF-7 and MDA-MB-231 cells in a dose-dependent manner (IC50=85.8 nM and 4.02 μM, respectively).
体内研究(In Vivo)
YL-109 (15 mg/kg; s.c. for every 2 d) inhibits both tumor growth and cancer metastasis of breast cancer cells in vivo.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
BALB/cAjcl-nu/nu female mice (4-5 weeks) inoculated with MCF-7 or MDA-MB-231 cells
Dosage:
15 mg/kg
Administration:
S.c. every 2 days for 63 days
Result:
Suppressed tumor growth in mice injected with MCF-7 and MDA-MB-231 cells.